Literature DB >> 15180875

Long-term improvement of anaemia in a patient with aplastic anaemia by short-term administration of pegylated recombinant human megakaryocyte growth and development factor.

Akira Matsuda, Motohiro Misumi, Maho Ishikawa, Fumiharu Yagasaki, Itsuro Jinnai, Masami Bessho, Hideaki Mizoguchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15180875     DOI： 10.1111/j.1365-2141.2004.04980.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.

Authors:  Yuji Yonemura; Hirosada Miyake; Norio Asou; Hiroaki Mitsuya
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  [Evaluation of the efficacy of cyclosporin A combined with recombined human thrombopoietin for treating patients with non-severe aplastic anemia].

Authors:  M L Zhang; W S Chen; B Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

3.  Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study.

Authors:  Yuan Yang; Zengwei Tang; Jiang Ji; Chen Yang; Miao Chen; Bing Han
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

4.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29

5.  The progression of severe aplastic anemia to hypoplastic leukemia in a long-term observation after the administration of pegylated rHuMGDF.

Authors:  Maho Ishikawa; Akira Matsuda; Daisuke Okamura; Tomoya Maeda; Nobutaka Kawai; Norio Asou; Masami Bessho
Journal:  Hematol Rep       Date:  2018-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.